 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Doxil- Doxil
- Ortho Biotech Brand of Doxorubicin Hydrochloride
Doxorubicin NC- Doxorubicin NC
- Neocorp Brand of Doxorubicin Hydrochloride
Doxotec- Doxotec
- Columbia Brand of Doxorubicin Hydrochloride
Farmiblastina- Farmiblastina
- Kenfarma Brand of Doxorubicin Hydrochloride
Myocet- Myocet
- Elan Brand of Doxorubicin Hydrochloride
Onkodox- Onkodox
- Onkoworks Brand of Doxorubicin Hydrochloride
Ribodoxo- Ribodoxo
- ribosepharm Brand of Doxorubicin Hydrochloride
Rubex- Rubex
- Bristol-Myers Squibb Brand of Doxorubicin Hydrochloride
Adriblastin- Adriblastin
- Pfizer Brand of Doxorubicin Hydrochloride
- Adriblastina
- Adriblastine
- Adriablastin
- Adriablastine
Adriamycin- Adriamycin
- Bedford Brand of Doxorubicin Hydrochloride
Adrimedac- Adrimedac
- medac Brand of Doxorubicin Hydrochloride
Caelyx- Caelyx
- Schering Brand of Doxorubicin Hydrochloride
- Schering-Plough Brand of Doxorubicin Hydrochloride
- Essex Brand of Doxorubicin Hydrochloride
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
- cell pharm Brand of Doxorubicin Hydrochloride
Doxolem- Doxolem
- Lemery Brand of Doxorubicin Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 2 | 2 | | 1981 | 0 | 2 | 2 | | 1982 | 1 | 5 | 6 | | 1983 | 0 | 4 | 4 | | 1984 | 0 | 5 | 5 | | 1985 | 2 | 2 | 4 | | 1986 | 0 | 2 | 2 | | 1987 | 1 | 2 | 3 | | 1988 | 1 | 4 | 5 | | 1989 | 3 | 2 | 5 | | 1990 | 1 | 2 | 3 | | 1991 | 2 | 3 | 5 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 1 | 1 | | 1994 | 2 | 2 | 4 | | 1995 | 2 | 2 | 4 | | 1996 | 0 | 3 | 3 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 6 | 6 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 2 | 3 | | 2001 | 5 | 5 | 10 | | 2002 | 1 | 4 | 5 | | 2003 | 0 | 3 | 3 | | 2004 | 2 | 8 | 10 | | 2005 | 0 | 8 | 8 | | 2006 | 2 | 4 | 6 | | 2007 | 2 | 8 | 10 | | 2008 | 1 | 3 | 4 | | 2009 | 0 | 6 | 6 | | 2010 | 6 | 5 | 11 | | 2011 | 4 | 6 | 10 | | 2012 | 1 | 8 | 9 | | 2013 | 3 | 7 | 10 | | 2014 | 3 | 3 | 6 | | 2015 | 3 | 5 | 8 | | 2016 | 1 | 6 | 7 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 3 | 3 | | 2019 | 2 | 3 | 5 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100.
-
Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, He M, Xiao Q, Sun M, Olopade OI, Zhao L, Wei M. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
-
Sasaki K, Ishihara J, Ishihara A, Miura R, Mansurov A, Fukunaga K, Hubbell JA. Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. Sci Adv. 2019 08; 5(8):eaaw6081.
-
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
-
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799.
-
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
-
Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
-
Knowles DA, Burrows CK, Blischak JD, Patterson KM, Serie DJ, Norton N, Ober C, Pritchard JK, Gilad Y. Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes. Elife. 2018 05 08; 7.
-
Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018 May; 5(5):e190-e200.
-
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|